Tyrosine kinase inhibitors regenerate non-cancerous tissue after cancer therapy
AssigneeThe Regents of the University of Colorado, a body corporate
InventorsMary Reyland, Sten Wie
Life of this patent
Estimating the term…
Abstract
Methods for inducing the regeneration of non-cancerous tissues in a cancer patient undergoing radiotherapy and/or chemotherapy using continuous administration of tyrosine kinase inhibitors for at least 90 days following a cancer treatment in the patient.
Claims23
A method for regenerating non-cancerous cells following treatment of a cancer patient, comprising administering a therapeutically effective amount of a tyrosine kinase inhibitor (TKI) for several months after administering a cancer treatment to a cancer patient.
A method of treating a cancer patient, the method comprising administering a tyrosine kinase inhibitor (TKI) to a cancer patient prior to administering a cancer treatment and thereafter continuously administering the TKI to the patient for at least 90-150 days following the administration of the cancer treatment.
A method for regenerating non-cancer tissues in a cancer patient, the method comprising administering a tyrosine kinase inhibitor (TKI) to a cancer patient prior to administering a cancer treatment and thereafter continuously administering the TKI to the patient for at least 90-150 days following the administration of the cancer treatment.
Dependencies are inferred from the claim text.